Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Extension Study of PF-07868489 in Adults With Pulmonary Arterial Hypertension
jRCT2031250407Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of PF-07868489 in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Primary endpoints: Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Change From Baseline in Laboratory Tests Results and 1 more. Started Nov 2025; status: active, not recruiting.
02
Drugs
PF-07868489
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2031250407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250407.